Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.140
Neutral
RSI(14)
29.354
Sell
STOCH(KDJ)(9,3,3)
61.014
Buy
ATR(14)
0.114
Low Volatility
CCI(14)
-19.858
Neutral
Williams %R
69.836
Sell
TRIX(12,20)
-4.496
Sell
StochRSI(14)
100.000
Overbought
Search
KALA BIO Inc
KALAAdd to Watchlist
0.781USD
+0.051+7.04%
Close 07-31 16:00（ET）Quotes delayed by 15 min
290.41KMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+7.04%
5 Days
+23.16%
1 Month
-56.12%
6 Months
-97.05%
Year to Date
-97.19%
1 Year
-88.46%
Key Figures
0.732Open
0.787High
71.72KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
19.29%Turnover Ratio
0.730Prev. Close
0.670Low
40.56KTurnover
LossP/E Static
0.03P/B
0.00%Div Yield TTM
-64.90%ROA
1030.00052wk High
0.93Volume Ratio
-38.51MNet Profit
371.80KShares
-102.0620EPS TTM
-2.38Beta
-238.69%ROE
2.10052wk Low
16.09%Amplitude
34.22%Gross Margin
290.41KMarket Cap
-7.36Reward/Risk
7.68%Risk Rate
TradingKey Stock Score of KALA BIO Inc
Currency: USD Updated: 2026-07-30Key Insights
KALA BIO Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 107 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 1.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
KALA BIO Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
KALA BIO Inc Highlights
StrengthsRisks
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
Overvalued
The company’s latest PE is -0.01, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 7.26M shares, increasing 38.84% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 18.58 shares of this stock.
Analyst Rating
Based on
2
analysts
Hold
Current Rating
1.500
Target Price
+80.07%
Upside Space
KALA BIO Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
2
analysts
Hold
Current Rating
1.500
Target Price
+80.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
KALA BIO Inc
KALA
2
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.698
Buy
MA10
0.695
Buy
MA20
0.931
Sell
MA50
1.856
Sell
MA100
5.164
Sell
MA200
10.546
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
KALA BIO Inc Info
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
Ticker SymbolKALA
CompanyKALA BIO Inc
CEOLazar (David Elliot)
Websitehttps://www.kalarx.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of KALA BIO Inc (KALA)?
The current price of KALA BIO Inc (KALA) is 0.78.
What is the symbol of KALA BIO Inc?
The ticker symbol of KALA BIO Inc is KALA.
What is the 52-week high of KALA BIO Inc?
The 52-week high of KALA BIO Inc is 1030.00.
What is the 52-week low of KALA BIO Inc?
The 52-week low of KALA BIO Inc is 2.10.
What is the market capitalization of KALA BIO Inc?
The market capitalization of KALA BIO Inc is 290.41K.
Is KALA BIO Inc (KALA) currently rated as Buy, Hold, or Sell?
According to analysts, KALA BIO Inc (KALA) has an overall rating of signal_hold, with a price target of 1.50.
What is the Earnings Per Share (EPS TTM) of KALA BIO Inc (KALA)?
The Earnings Per Share (EPS TTM) of KALA BIO Inc (KALA) is -165.56.